Showing results (471-480 of 661) with videos related to
Sort By:
Pageof 67
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 28, 2024
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trialYoon-Koo Kang, Min-Hee Ryu, Maria Di Bartolomeo, et al.Annals of Surgical Oncology|October 18, 2022
The Cancer Hub Approach for Upper Gastrointestinal Surgery During COVID-19 Pandemic: Outcomes from a UK Cancer CentreJoseph P Doyle, Pranav H Patel, Sophie L F Doran, et al.Applied Health Economics and Health Policy|October 22, 2016
Ethical Hurdles in the Prioritization of Oncology CareFolkert de Groot, Stefano Capri, Jean-Claude Castanier, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort studyAnthony J Swerdlow, Craig D Higgins, Paul Smith, et al.Molecular Cancer Therapeutics|July 3, 2019
Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant CancersAdam Stewart, Elizabeth A Coker, Sebastian Pölsterl, et al.The Lancet. Oncology|June 4, 2013
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trialMatthew T Seymour, Sarah R Brown, Gary Middleton, et al.Heart (British Cardiac Society)|July 24, 2014
Device-dependent association between paravalvar aortic regurgitation and outcome after TAVIRafal Dworakowski, Olaf Wendler, Brian Halliday, et al.British Journal of Cancer|September 14, 2016
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumabCharles S Fuchs, Josep Tabernero, Jiří Tomášek, et al.The Lancet. Oncology|December 25, 2025
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trialJong-Mu Sun, Yee Chao, Sung-Bae Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2011
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusEric Van Cutsem, Claus-Henning Köhne, István Láng, et al.Pageof 67